Isatuximab, Dexamethasone, and Lenalidomide for Frail Multiple Myeloma Patients
Phase 2
40
about 2.1 years
18+
1 site in UT
What this study is about
This trial is testing a go-slow approach to treating multiple myeloma in very frail patients. The treatment starts with Isatuximab and dexamethasone, then gradually introduces lenalidomide. The goal is to see if this gentler start improves how well people stick to their treatment plan and improves their quality of life.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Isatuximab
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
isatuximab
Secondary: Change in quality of life as per the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 domain, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by duration, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by relationship to study treatment, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by seriousness, Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by severity (as defined by the NIH CTCAE, version 5.0), Frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, Overall survival (OS)
Oncology